• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
Home
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Pharma
    • Asia
    • Drug Delivery
    • Executives
    • Clinical Data
  • Vaccines
  • Special Reports
  • Trending
    • COVID-19
    • Cell & Gene Therapy
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Search Icon
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Pharma
    • Asia
    • Drug Delivery
    • Executives
    • Clinical Data
  • Vaccines
  • Special Reports
  • Trending
    • COVID-19
    • Cell & Gene Therapy
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events

Jakafi

Pharma

J&J, AbbVie's Imbruvica is first drug to treat kids with cGVHD

Johnson & Johnson and AbbVie’s Imbruvica has gained its first pediatric nod. This one is for chronic graft-versus-host disease.
Kevin Dunleavy Aug 25, 2022 9:37am

Incyte's Opzelura slapped with vitiligo decision delay

Mar 14, 2022 11:28am

Incyte's eczema cream Opzelura combats payer hurdles: exec

Nov 2, 2021 10:55am

Jakafi maker Incyte channels blood test anxiety in awareness ads

Oct 12, 2021 11:05am

Incyte snags 2nd JAK nod in 2 days—this time for Jakafi

Sep 23, 2021 10:20am

Incyte still counts on Jakafi, rux cream September PDUFAs

Aug 4, 2021 11:12am
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2023 Questex LLC All rights reserved.
Terms of use
Privacy Policy